Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Ivor John Percent"'
Autor:
Bradley Curtis Carthon, Jesus Zoco, Thomas E. Hutson, Mark R. Olsen, Edward Arrowsmith, Johanna C. Bendell, Hamid Emamekhoo, Joshua Zhang, Daniel J. George, Scott S. Tykodi, David Leung, Ana M. Molina, Alexandra Drakaki, Lucio N. Gordan, Ivor John Percent, Daniel C. Cho, Jennifer L. Johansen, Arash Rezazadeh Kalebasty
Publikováno v:
Cancer. 128:966-974
Background Nivolumab plus ipilimumab (NIVO + IPI) has demonstrated long-term efficacy and safety in patients with previously untreated, advanced renal cell carcinoma (aRCC). Although most phase 3 clinical trials exclude patients with brain metastases
Autor:
Wen Hong Lin, Carlos H. Barrios, Martin Reck, Ramaswamy Govindan, Neal Ready, Dimple Pandya, Hye Ryun Kim, Taofeek K. Owonikoko, Alejandro Navarro, Keunchil Park, Laurent Greillier, Ivor John Percent, Vanesa Gutierrez, Miten Patel, Jong Seok Lee, Parul Doshi, Michael Schenker, Solange Peters, Shaker R. Dakhil, Jerónimo Rodríguez-Cid, Daniel Morgensztern, Christine Baudelet, Sofia Baka, Jonathan F. Baden, Giovanni Selvaggi
Publikováno v:
Journal of clinical oncology, vol. 39, no. 12, pp. 1349-1359
Scientia
Journal of Clinical Oncology
Journal of Clinical Oncology, 2021, 39 (12), pp.1349-1359. ⟨10.1200/JCO.20.02212⟩
Scientia
Journal of Clinical Oncology
Journal of Clinical Oncology, 2021, 39 (12), pp.1349-1359. ⟨10.1200/JCO.20.02212⟩
PURPOSE In extensive-disease small-cell lung cancer (ED-SCLC), response rates to first-line platinum-based chemotherapy are robust, but responses lack durability. CheckMate 451, a double-blind phase III trial, evaluated nivolumab plus ipilimumab and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::362dcb13447f71920cccc0d1cd6b0b79
https://serval.unil.ch/resource/serval:BIB_78F0D04B7BA3.P001/REF.pdf
https://serval.unil.ch/resource/serval:BIB_78F0D04B7BA3.P001/REF.pdf
Autor:
Xin Gao, Howard A. Burris III, Jacqueline Vuky, Robert Dreicer, A. Oliver Sartor, Cora N. Sternberg, Ivor John Percent, Maha H. A. Hussain, Arash Rezazadeh Kalebasty, John Shen, Elisabeth I. Heath, Guillermo Abesada-Terk, Sunil G. Gandhi, Meredith McKean, Haolan Lu, Elmer Berghorn, Richard Gedrich, S. Debbie Chirnomas, Nicholas J. Vogelzang, Daniel P. Petrylak
Publikováno v:
Journal of Clinical Oncology. 40:17-17
17 Background: ARV-110 is a first-in-class, oral PROteolysis TArgeting Chimera (PROTAC) protein degrader that selectively targets AR. Patients (pts) with mCRPC have limited treatment (tx) options due to decreasing AR dependence of tumors upon success
Autor:
Susanna Varkey Ulahannan, Ivor John Percent, Edward Arrowsmith, Maen A. Hussein, Viralkumar K. Bhanderi, John Hamm, Greg Andrew Durm, Damijan Erzen, Prasant Mohanty, David R. Spigel
Publikováno v:
Journal of Clinical Oncology. 40:98-98
98 Background: Anti-PD-1 antibodies may have synergistic effects with other immunomodulatory or targeted agents. This open-label, Phase II platform trial is investigating ezabenlimab, an anti-PD-1 antibody, combined with other agents. Module C of the
Autor:
Maen A. Hussein, Ivor John Percent, Johanna C. Bendell, Edward Arrowsmith, Hendrik-Tobias Arkenau, Quincy S. Chu, Aaron Richard Hansen, Damijan Erzen, Sheng Qiu, Anthony Lucarelli, Susanna Varkey Ulahannan
Publikováno v:
Journal of Clinical Oncology. 39:2582-2582
2582 Background: The combination of anti-PD-1 antibodies with other immunomodulatory or targeted therapies has the potential for synergistic effects. This open-label, Phase II platform trial is assessing ezabenlimab, an anti-PD-1 antibody, in combina
Autor:
S. Lam, Alexander I. Spira, Maen A. Hussein, Davey B. Daniel, Steven L. McCune, T. Ton, Ivor John Percent, S. Morris, Aaron S. Mansfield, A. Johnson, J. Goldschmidt, Leora Horn, Tarek Mekhail, S. Whipple, R. Induru, Fadi Braiteh, G. Macvicar, Ticiana A. Leal
Publikováno v:
Journal of Thoracic Oncology. 14:S1018-S1019
Autor:
Heidi Ann McKean, Joshua Zhang, Daniel J. George, Scott S. Tykodi, Jennifer L. Johansen, Jeffrey Yorio, Sunil Babu, Bradley Curtis Carthon, Michael R. Harrison, Jesus Zoco, Thomas E. Hutson, Ivor John Percent
Publikováno v:
Journal of Clinical Oncology. 39:315-315
315 Background: Combination therapy with nivolumab + ipilimumab (NIVO+IPI) has demonstrated long-term efficacy and tolerability for patients (pts) with previously untreated advanced renal cell carcinoma (aRCC). Most pivotal clinical trials in pts wit
Autor:
Daniel J. George, Robert S. Alter, Rakesh Singal, Peter J. Van Veldhuizen, Ivor John Percent, Michael R. Harrison, Joshua Zhang, Lucio N. Gordan, Arash Rezazadeh Kalebasty, Jennifer L. Johansen, Edward Arrowsmith, Scott S. Tykodi, Jesus Zoco, Thomas E. Hutson
Publikováno v:
Journal of Clinical Oncology. 39:309-309
309 Background: The long-term efficacy and tolerability of nivolumab (NIVO) 3 mg/kg + ipilimumab (IPI) 1 mg/kg Q3W × 4 doses followed by NIVO 3 mg/kg Q2W for previously untreated advanced RCC (aRCC) demonstrated in the registrational CheckMate 214 c
Autor:
Quincy Chu, Zhichao Sun, Johanna C. Bendell, Aaron R. Hansen, Damijan Erzen, Ivor John Percent, Hendrik-Tobias Arkenau, Anthony Lucarelli, Maen A. Hussein
Publikováno v:
Journal of Clinical Oncology. 39:TPS152-TPS152
TPS152 Background: Combining anti-programmed cell death protein 1 (PD-1) antibodies with other immuno-modulatory or targeted therapies may improve outcomes. NCT03697304 is an open-label, Phase II, platform trial assessing BI 754091, an anti-PD-1 anti
Autor:
Ivor John Percent, Manabu Morimoto, Aaron R. Hansen, Shunsuke Kondo, Ben George, Mabrouk Elgadi, Melissa Lynne Johnson, Johanna C. Bendell, Yoon-Koo Kang, Maen A. Hussein, Manish R. Patel, Christine Duffy, Miaomiao Ge, Maren Rohrbacher, Mohamad Cherry, Shigehisa Kitano, Do-Youn Oh, Kensei Yamaguchi, Edward Arrowsmith
Publikováno v:
Journal of Clinical Oncology. 38:3063-3063
3063 Background: LAG-3, an immune checkpoint receptor involved in T-cell regulation, is frequently co-expressed with PD-1. LAG-3 and PD-1 signaling contributes to immune cell exhaustion and reduces the immune response to tumor cells. Dual inhibition